FDA accepts Idec's Zevalin BLA

Idec (IDPH) said the FDA accepted its resubmission of the BLA for Zevalin to treat low grade, follicular, CD20-positive transformed, relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) and Rit...